Form 8-K · Current report
Biogen 8-K, filed Jul 29, 2026
- Filed
- CIK
- 0000875045
- Accession no.
- 0000875045-26-000073
Summary
Biogen Inc. reported strong financial results for the second quarter of 2026, achieving total revenue of $2.7 billion and seeing its growth portfolio generate $1.06 billion. The company highlighted successful commercial momentum, including the launch of LEQEMBI IQLIK, and stated it anticipates releasing five registrational readouts from its late-stage pipeline over the next four quarters.
Key points
- Total revenue for the second quarter of 2026 was $2.7 billion, reflecting a 3% year-over-year increase.
- Biogen reported the historic FDA approval of LEQEMBI IQLIK for at-home administration of the anti-amyloid treatment.
- The Apellis acquisition has been completed, with Biogen projecting the transaction to be accretive to Non-GAAP diluted EPS in 2027.
- The company plans to release five registrational data readouts from its late-stage pipeline over the next four quarters.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 29, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.